Skyrizi Pen
Generic name: risankizumab [ RIS-an-KIZ-ue-mab ]
Brand names: Skyrizi, Skyrizi Pen
Drug class: Interleukin inhibitors
What is Skyrizi Pen?
Skyrizi Pen is used alone or in combination in adults to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
Skyrizi Pen is also used in adults to treat Crohn's disease.
Skyrizi Pen may also be used for purposes not listed in this medication guide.
Skyrizi Pen side effects
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:
-
fever, night sweats, chills, sore throat;
-
mouth sores, red or swollen gums;
-
pale skin, easy bruising, unusual bleeding; or
-
chest discomfort, wheezing, dry cough or hack, rapid weight loss.
Also call your doctor at once if you have:
-
nausea, vomiting, skin rash; or
-
liver problems--loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Your treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of Skyrizi Pen may include:
-
fever, headache, tiredness;
-
stomach pain, joint pain, back pain;
-
cold symptoms such as stuffy nose, sneezing, sore throat;
-
pain and burning when you urinate;
-
fungal skin infection;
-
low red blood cells (anemia); or
-
pain, bruising, swelling, or irritation where the medicine was injected.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Related/similar drugs
Entyvio, Cimzia, Otezla, Taltz, Sotyktu, prednisone, methotrexate
Warnings
You may get infections more easily, even serious or fatal infections. Call your doctor if you have flu symptoms, cough, night sweats, neck stiffness, confusion, or vision problems. Before you use Skyrizi Pen, your doctor should test you for tuberculosis or other infections.
Before taking this medicine
You should not use Skyrizi Pen if you are allergic to it.
Before you start using Skyrizi Pen, tell your doctor if you have any signs of infection such as fever, chills, cough, body aches, tiredness, open sores, or skin wounds, diarrhea, stomach pain, weight loss, painful urination, or coughing up blood.
Tell your doctor if you have or ever had:
-
an active, chronic, or recent infection;
-
tuberculosis, been exposed to tuberculosis, or if you recently traveled;
-
recently received or are scheduled to receive any vaccine; or
Make sure you are current on all vaccines before you start using Skyrizi Pen.
If you are pregnant, your name may be listed on a pregnancy registry to track the effects of risankizumab on the baby.
It is not known if Skyrizi Pen will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
Ask a doctor if it is safe to breastfeed while using Skyrizi Pen.
How should I use Skyrizi Pen?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Before you use Skyrizi Pen, your doctor will test you for tuberculosis or other infections.
If you have Crohn's disease, Skyrizi Pen is given as an infusion into a vein by a healthcare provider every 4 weeks for the first 3 doses. Later doses are then injected under the skin once every 8 weeks.
If you have plaque psoriasis and psoriatic arthritis, Skyrizi Pen is injected under the skin every 4 weeks for the first 2 doses. Later doses are then injected every 12 weeks.
A healthcare provider may give you this injection or teach you how to properly use this medicine by yourself. Ask your doctor or pharmacist if you don't understand how to use a prefilled syringe, an injection pen, or the injector device placed on the body.
A full dose of risankizumab may require more than one injection under the skin. Your healthcare provider will show you where to inject Skyrizi Pen. Do not inject into the same place two times in a row. Avoid injecting into skin that is hard, red, bruised, swollen, tender, or affected by psoriasis.
Prepare an injection only when you are ready to give it. Call your pharmacist if the medicine looks cloudy, has changed colors or has particles in it.
Each injection is for one use only. Throw away after one use, even if there is still medicine left inside. Place it in a puncture-proof "sharps" container and dispose of it following state or local laws. Keep out of the reach of children and pets.
Throw away any Skyrizi Pen that has been shaken, frozen, or damaged in any way.
You may get infections more easily, even serious or fatal infections. You will need frequent medical tests.
You will need frequent blood tests to check your liver function.
Take the medicine out of the refrigerator and follow the instructions to let it reach room temperature before using the medicine. Do not warm the medicine with hot water, sunlight, or a microwave.
Store the medicine in the original container in the refrigerator. Protect from light and do not freeze.
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Skyrizi Pen infusion.
Use the medicine as soon as you remember, and then go back to your regular schedule. Do not use two doses at one time.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
What should I avoid while using Skyrizi Pen?
Avoid receiving a "live" vaccine, or you could develop a serious infection. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), and zoster (shingles).
What other drugs will affect Skyrizi Pen?
Other drugs may affect Skyrizi Pen, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Popular FAQ
Skyrizi has no warnings or precautions for malignancy (cancer) in its product label and cancer is not listed as a serious or common side effect. Continue reading
In a head-to-head clinical study between Skyrizi and Humira, researchers found that Skyrizi was better than Humira at clearing moderate-to-severe plaque psoriasis in adults. At 16 weeks, 72% of patients given Skyrizi achieved 90% clearer skin compared to 47% of patients given Humira, a statistically significant outcome. Continue reading
Yes, Skyrizi was approved in January 2022 to treat psoriatic arthritis in adults. Skyrizi was also approved in April 2019 to treat moderate-to-severe plaque psoriasis in adults. A third indication, moderate-to-severe Crohn's disease in adults, was cleared by the FDA in June 2022. Continue reading
Skyrizi is made by AbbVie Inc., a pharmaceutical company located in North Chicago, Illinois. You can contact Abbvie at 1-800-222-6885. Skyrizi is used for the treatment of plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. Continue reading
There are a number of differences between Skyrizi and Ilumya:
- Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019.
- Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab
- The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time
- Ilumya needs to be administered by a healthcare professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home
- Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA).
More FAQ
More about risankizumab
- Check interactions
- Compare alternatives
- Reviews (45)
- Side effects
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2024 Cerner Multum, Inc. Version: 6.01.
